• Investment World
• eWorld
• Catalyst
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad , Jan. 8

AUROBINDO Pharma Ltdhas announced that it has received its first Certificate of Suitability (CoS) approval from the European Directorate for Quality Medicines (EDQM) for its product in the therapeutic segment of gastroenterology.

The company filed two more drug master files (DMFs) with the United States Food and Drug Administration, making the total number of filings to three. Of this, two were in category of central nervous system (CNS) and one in diabetology. The latest DMF was for Citalopram, an antidepressant, the company informed stock exchanges on Wednesday. By virtue of CoS, the company expects to gain entry into the European Union (EU) pharmaceutical market. The company said it expects to receive such approvals on a routine basis here after.

More Stories on : Standards & Benchmarks | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Hero Honda may consider interim

Copyright © 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line